Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of two doses of safinamide
(50 and 100 mg/day, p.o.), compared to placebo, as add-on therapy in patients with idiopathic
Parkinson's disease with motor fluctuations who are currently receiving a stable dose of
levodopa.